Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

160 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Genes in the HLA class I region may contribute to the HLA class II-associated genetic susceptibility to multiple sclerosis.
Harbo HF, Lie BA, Sawcer S, Celius EG, Dai KZ, Oturai A, Hillert J, Lorentzen AR, Laaksonen M, Myhr KM, Ryder LP, Fredrikson S, Nyland H, Sørensen PS, Sandberg-Wollheim M, Andersen O, Svejgaard A, Edland A, Mellgren SI, Compston A, Vartdal F, Spurkland A. Harbo HF, et al. Among authors: mellgren si. Tissue Antigens. 2004 Mar;63(3):237-47. doi: 10.1111/j.0001-2815.2004.00173.x. Tissue Antigens. 2004. PMID: 14989713
Corticosteroids in the treatment of multiple sclerosis.
Myhr KM, Mellgren SI. Myhr KM, et al. Among authors: mellgren si. Acta Neurol Scand Suppl. 2009;(189):73-80. doi: 10.1111/j.1600-0404.2009.01213.x. Acta Neurol Scand Suppl. 2009. PMID: 19566504 Review.
Health-related quality of life in secondary progressive multiple sclerosis.
Beiske AG, Naess H, Aarseth JH, Andersen O, Elovaara I, Farkkila M, Hansen HJ, Mellgren SI, Sandberg-Wollheim M, Sorensen PS, Myhr KM; Nordic SPMS study group. Beiske AG, et al. Among authors: mellgren si. Mult Scler. 2007 Apr;13(3):386-92. doi: 10.1177/13524585070130030101. Mult Scler. 2007. PMID: 17439908
Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis.
Andersen O, Elovaara I, Färkkilä M, Hansen HJ, Mellgren SI, Myhr KM, Sandberg-Wollheim M, Soelberg Sørensen P. Andersen O, et al. Among authors: mellgren si. J Neurol Neurosurg Psychiatry. 2004 May;75(5):706-10. doi: 10.1136/jnnp.2003.010090. J Neurol Neurosurg Psychiatry. 2004. PMID: 15090564 Free PMC article. Clinical Trial.
[New diagnostic criteria in multiple sclerosis].
Midgard R, Beiske AG, Celius EG, Jensen D, Hovdal H, Mellgren SI, Myhr KM. Midgard R, et al. Among authors: mellgren si. Tidsskr Nor Laegeforen. 2003 May 15;123(10):1345-8. Tidsskr Nor Laegeforen. 2003. PMID: 12806674 Review. Norwegian. No abstract available.
NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.
Sorensen PS, Mellgren SI, Svenningsson A, Elovaara I, Frederiksen JL, Beiske AG, Myhr KM, Søgaard LV, Olsen IC, Sandberg-Wollheim M. Sorensen PS, et al. Among authors: mellgren si. Lancet Neurol. 2009 Jun;8(6):519-29. doi: 10.1016/S1474-4422(09)70085-7. Epub 2009 May 4. Lancet Neurol. 2009. PMID: 19409854 Free article. Clinical Trial.
160 results